The Venture Codex Logo

The Venture Codex

Overview

Healthcare IT systems company focused on interoperability and cooperation.

Founded

1990

Deals · 12mo

0

Stage focus

Series B

Geographic focus

United States

Sector focus

Health Care
Information Technology
Software

Investment portfolio

1rounds
NAMEDATESIZE
ObvioHealth
Jul 2021Led
$31 MSeries B
ObvioHealth
Jul 2021Led
$31 MSeries B
1
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Dedalus Group: 1 funding rounds are recorded in the selected participation categories.All available history.
Dedalus Group: 1 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series B10

Monthly Deal Activity

Dedalus Group: 1 deals are recorded across 64 months.All available history.
Dedalus Group: 1 deals are recorded across 64 months. All available history
MonthDeals
Jul '211
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Dedalus Group: Health & Life Sciences is the largest displayed sector by deal count (1 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Dedalus Group: Health & Life Sciences is the largest displayed sector by deal count (1 deals). All available history
SectorDeals
Health & Life Sciences1

Deal Size Distribution

Dedalus Group: 1 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Dedalus Group: 1 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M1
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Dedalus Group: United States has the largest recorded deal count among the displayed regions (1 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Dedalus Group: United States has the largest recorded deal count among the displayed regions (1 deals). All available history
RegionDeals
United States1
Dedalus Group: 3 co-investors are shown, with AT Capital Group sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Dedalus Group: 3 co-investors are shown, with AT Capital Group sharing 1 recorded deals. All available history
Co-investorShared deals
AT Capital Group1
Novotech Health Holdings1
SPRIM Global Investments1

Investment Strategy

Dedalus Group: Led accounts for 100% and participating for 0% of round participation.All available history.
Dedalus Group: Led accounts for 100% and participating for 0% of round participation. All available history
CategoryDeals (count)Share (%)
Led1100%
Participating00%
Dedalus Group: Single-lead accounts for 0% and co-led for 100% of lead dynamics.All available history.
Dedalus Group: Single-lead accounts for 0% and co-led for 100% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led1100%

Team

Chris Masci

Vice President of Business Development

Giorgio Moretti

Executive Chairman

Lapo Bertini

Director of Interoperability Product Stretegy

Maciej Gorczynski

Frontend Developer

Mariagrazia Cinti

Software Analyst

Marlen Suller

Head of In-Vitro Diagnostic Business Unit

Michael Dahlweid

Group Product & Clinical Officer